Ligand Pharmaceuticals (LGND) Current Assets (2010 - 2026)

Ligand Pharmaceuticals (LGND) has 17 years of Current Assets data on file, last reported at $865.4 million in Q1 2026.

• For the quarter ending Q1 2026, Current Assets rose 179.78% year-over-year to $865.4 million; the trailing twelve-month figure through Mar 2026 stood at $865.4 million (up 179.78% YoY), and the FY2025 full-year result was $832.3 million, up 151.02% from the prior year.
• Current Assets grew to $865.4 million in Q1 2026, from $832.3 million in the prior quarter.
• In the past five years, Current Assets ranged from a high of $865.4 million in Q1 2026 to a low of $220.4 million in Q3 2022.
• A 5-year average of $384.5 million and a median of $309.4 million in 2024 frame the typical range for Current Assets.
• Across the five-year window, Current Assets tumbled 48.98% in 2022 and soared 179.78% in 2026, its largest moves.
• Tracing LGND's Current Assets over 5 years: stood at $263.6 million in 2022, then fell by 9.93% to $237.4 million in 2023, then surged by 39.65% to $331.6 million in 2024, then surged by 151.02% to $832.3 million in 2025, then grew by 3.98% to $865.4 million in 2026.
• Business Quant data shows LGND's Current Assets at $865.4 million in Q1 2026, $832.3 million in Q4 2025, and $753.9 million in Q3 2025.